Day 2 :
Augurix SA, Switzerland
Time : 09:30-10:10
Dr. Cécile Besson Duvanel was awarded a fellowship from the Roche Research Foundation to conduct her MD-PhD thesis in the field of immunochemistry in 2002 at the University of Lausanne, Switzerland. She then completed her MD training at the Pediatric Department of the University Hospital in Lausanne. She has been awarded several international distinctions for her research, including the Milupa Neonatology Award and the Professor Combe Award, and she has authored more than 20 scientific publications in international, peer-reviewed journals. She co-founded Augurix SA in 2007, a start-up active in the development of companion diagnostics in the field of gastroenterology.
Abdominal pain, cramping, bloating, constipation, diarrhoea are all very common clinical symptoms that generate more than 70 million physician visits annually in Europe and over 94 million in the United States. Usually, patients suffering from these symptoms consult at the primary care, where physicians will need to discriminate patients with a benign functional GI disorder, typically irritable bowel syndrome from those suffering from an organic disorder, either with inflammatory etiology, autoimmune etiology (celiac disease), infectious or oncology etiology. Today, good predictors of the severity of digestive disorders and their outcome are still lacking in current medical practice. The state-of-the-art is still based on endoscopic procedures and several publications have demonstrated increasing evidence that endoscopy parameters are better predictors to help identifying patients who should be treated with more aggressive therapies. The most recent advances are in the field of confocal laser endomicroscopy, a technique that allows real time in vivo histology of 1’000-fold magnification during on-going endoscopy. Endomicroscopy requires the application of fluorescent agents either systemically or topically. However, the fluorescent agents currently used are non-specific, thereby limiting the ability to discriminate the different disorders. Therefore, there is a need for diagnostic agents which are non-toxic and which are not hydrolysable or absorbable by the organism. In particular, when the diagnostic agent is to be in contact with a mucous membrane, it is of importance that this agent does not present a non-specific adhesion to the mucous membrane, so that the entire administered dose reaches the target area.
Menoufia University, Egypt
Time : 10:10-10:50
Ehab Abd-El-Atty has completed his PhD from Faculty of Medicine, Menoufia University, Egypt and Master degree of Medical Sciences from Faculty of Medicine, Catholic University, Leuven, Belgium. He is Professor of Internal Medicine, Hepatology and Gastroenterology, Faculty of Medicine, Menoufia University, Egypt. He has published more than 30 papers in reputed journals and has been serving as a reviewer of Menoufia Medical Journal (MMJ). He is a member of AASLD (American Association for the Study of the Liver Diseases), ESGE (European Society of Gastrointestinal Endoscopy) and EASL (European Association for the Study of the Liver).
Gastrointestinal (GI) bleeding is a common clinical problem and one of the most important emergencies in gastroenterology. UGIT bleeding may be due to general causes (Coagulation defects or Bleeding disorders) or local causes (Esophageal, Gastric lesions or duodenal lesions). Mortality rate is still high about 5%–10% in patients with peptic ulcer bleeding and about 15% in those with variceal hemorrhage. 5-10% of patients will not be initially controlled by endoscopic intervention or they will experience a recurrence of bleeding in the first 24 to 72 hours. Hemospray (TC-325) is a novel hemostatic agent for the treatment of uncontrolled gastrointestinal bleeding (Variceal hemorrhage, Peptic ulcer, colonic ulcer, bleeding malignant tumors). It is a hemostatic spray propelled by carbon dioxide under pressure, which can achieve rapid hemostasis 92-100% of the cases. The powder forms a barrier over the vessel wall, quickly stopping the bleeding and increases the local concentration and activating platelets and of clotting factors and enhances thrombus formation. It is not absorbed or metabolized by mucosal tissue (no risk of systemic toxicity). Hemostatic spray is safe, quick, simple and easy. It does not require very precise targeting such as deployment of hemoclips. It covers a large surface area as bleeding malignant tumors. The effects of the spray disappear within 24 h to 72 hour. It stops uncontrolled GIT bleeding in 93-100% of cases. Hemospray appears to allow safe control of acute bleeding and may be used in high-risk cases as a temporary measure or a bridge toward more definitive therapy.